Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled PC786 for RSV in HSCT Recipients
NCT03715023Phase 2Terminated
- Sponsor
- Pulmocide
- Start
- Nov 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PC786 in respiratory syncytial virus infection (RSV), sponsored by Pulmocide. Started Nov 2018; status: terminated.
02
Drugs
PC786
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03715023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03715023.